

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Mega Genomics Limited

美因基因有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6667)

PROFIT WARNING

This announcement is made by Mega Genomics Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company that, based on the preliminary assessment on the Group’s unaudited consolidated management accounts for the year ended 31 December 2022 and the information currently available to the Board, the Group is expected to record a net loss attributable to owners of the parent for the year ended 31 December 2022 of approximately RMB13 million to RMB22 million (the net profit attributable to owners of the parent for the year ended 31 December 2021: RMB79 million). Such expected decrease is mainly due to the following reasons:

In the year ended 31 December 2022, a nationwide outbreak of several rounds of COVID-19 pandemic occurred, prompting the government to implement strict control measures against the pandemic. As a result, many large and medium-sized cities across the country enforced traffic restrictions, causing the frequent closure of stores by the Company’s customers or severe restrictions on their operations. Consequently, the Company’s revenue decreased significantly while the costs of rent, labor and depreciation remained relatively fixed. In addition, with the further advancement of the research and development process, the Company increased its investment in research and development in the year ended 31 December 2022, with an increase in the number of research and development staff, and an increase in investments related to research and development materials and clinical trials, resulting in a significant increase in research and development expenses.

The information contained in this announcement is based solely on the preliminary assessment made by the Board based on the unaudited consolidated management accounts of the Group for the year ended 31 December 2022 and the information available to the Board as at the date of this announcement. These accounts and information have not been reviewed, confirmed or audited by the Company’s auditors and/or audit committee and may be subject to adjustment. The Group is in the process of preparing and finalizing the Group’s annual results for the year ended 31 December 2022. Details of the financial information of the Group for the year ended 31 December 2022 will be disclosed in the annual results announcement which is expected to be published on 31 March 2023.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Mega Genomics Limited
LIN Lin
Executive Director and Chairperson

Hong Kong, 20 March 2023

As at the date of this announcement, the executive Directors are Dr. Yu Rong, Ms. Lin Lin, Mr. Huang Yufeng and Ms. Jiang Jing; the non-executive Director is Ms. Guo Meiling; and the independent non-executive Directors are Dr. Zhang Ying, Mr. Jia Qingfeng and Dr. Xie Dan.